Bioactive Compound: Butyrate

Modulation of gut microbiome in response to the combination of Escherichia coli Nissle 1917 and sugars: a pilot study using host-free system reflecting impact on interpersonal microbiome

mycolabadmin

This study examined how a beneficial bacteria called Escherichia coli Nissle 1917 combined with different types of sugar affects gut bacteria. Researchers found that the effectiveness of these treatments depends heavily on each person’s unique starting microbiota composition, which is shaped by their diet, lifestyle, and health status. The results show that one-size-fits-all probiotic treatments don’t work equally for everyone, and doctors should personalize treatments based on an individual’s existing gut bacteria profile.

Read More »

Nutritional strategies in supporting immune checkpoint inhibitor, PI3K inhibitor, and tyrosine kinase inhibitor cancer therapies

mycolabadmin

This review examines how nutrition and food-based interventions can improve cancer treatment outcomes for patients receiving targeted cancer therapies. A Mediterranean-style diet with plenty of fiber (30-50g daily) appears beneficial for patients on immune checkpoint inhibitor therapies by promoting healthy gut bacteria that support immune function. The review also discusses promising research on fermented foods, specific bacterial supplements, mushroom extracts, and fasting approaches as complementary strategies to enhance cancer treatment effectiveness while reducing side effects.

Read More »
Scroll to Top